fbpx Yourgene Health plc - Home
003-news.jpg
001-news.jpg
002-news.jpg
DSC00185r.jpg
004-news.jpg
previous arrow
next arrow

Ranger® Revolution - LightBench® Detect is Here!

The wait is over! Yourgene Health are proud to today reveal the Ranger® Revolution in the form of the LightBench® Detect; the latest addition to our Ranger® Technology portfolio. We’ve worked closely with our clinical laboratory partners to develop a size selection instrument that is optimised for improving the performance of liquid biopsy workflows, most notably non-invasive prenatal testing (NIPT). The LightBench® Detect addresses a pressing need for NIPT providers to be able to reduce no-call rates by optimising average fetal fraction. Additionally, by leveraging patent-pending size-selection technology from Yourgene Health, the LightBench® Detect is the only size-selection instrument that enables laboratories to consider the use of EDTA blood collection tubes (BCTs) instead of Streck BCTs.

Ranger® Technology in NIPT – 3-in-1 Solution

Ranger® Technology offers industry-leading scalability and precision for the DNA size selection process. The core size selection functionality is complemented by the ability to perform fragment length analysis and fluorescence assays for quality control purposes. Since cfDNA fragments of fetal origin are typically <150bp in length, size selection using Ranger® Technology can enrich for fetal fraction to reduce the number of no-call results or screening failures. Use of the technology in NIPT has already been demonstrated to secure an average recovery yield of over 70%. Unlike traditional electrophoretic size selection approaches, >97% reproducibility is possible, and ensures consistent enrichment of the fetal fraction.

The existing LightBench® specifically addresses the needs of research applications, including metagenomics and sequence discovery.

EDTA BCTs in NIPT

Recent work presented by the Centre de recherche du CHU de Québec-Université Laval, demonstrated a patent-pending ability of Ranger® Technology to enable laboratories to consider the use of EDTA BCTs instead of Streck BCTs in their workflows (1). The group worked with Yourgene Health to compare fetal fraction in 61 samples collected from singleton pregnancies in Vancouver over a two month period. Each pregnancy had two 10mL peripheral blood samples taken; one in EDTA and one Streck. Samples from EDTA tubes with size selection had no failures, and an average fetal fraction of 13%; a significant increase compared to Streck tubes (7%). They concluded that the addition of this size-selection step is ‘a strategy that significantly increases fetal fraction and reduces the number of no-call results due to low fetal fraction…[this is] a cost-saving measure for the laboratory and benefits women’ (1). In doing so, they demonstrated that Ranger® Technology offers an alternative solution to the use of Streck BCTs for stabilising NIPT samples. Dr François Rousseau from the Université Laval presented this work at the Labroots 2022 Genetics Virtual Week event, and you can watch an on demand recording.

Yourgene Health have now made this capability accessible to the market exclusively via the LightBench® Detect. Ranger® Technology is the only size-selection methodology capable of offering this flexibility in BCT choice.

LightBench® Detect

The LightBench® Detect is currently the only instrument in the Ranger® portfolio capable of leveraging the patent-pending EDTA size selection approach tested by the Laval group. Yourgene Health have conducted extensive analysis in collaboration with our clinical laboratory partners to understand both the potential clinical and economic benefits that could be achieved in adopting the LightBench® Detect. You can read the results of this analysis in our Your Expert article on cost savings here.

Ranger® Roadmap

At this time, the development will only be accessible to Yourgene’s non-IONA® Nx NIPT customers, including Sage™ 32plex, as the feature is not yet available on the QS250. The Yourgene® QS250 is optimised for use in Yourgene’s end-to-end NIPT workflow offerings. This decision is part of Yourgene’s recently announced commitment to a next-generation approach to delivery of NIPT testing solutions, with a focus on ‘Collaboration to Perform’. Working as a partnership, rather than the traditional laboratory/manufacturer relationship, represents a shared commitment to ensuring high-quality and performance-driven testing, ultimately delivering better outcomes for patients. For these reasons, we are first collaborating with a subset of IONA® Nx customers to collect robust validation data to support the proper utilisation of this development within the QS250 i.e. a CE-IVD environment. We anticipate these validation studies will be completed within 2022, at which time we will begin development within the IONA® workflow.

Liquid Biopsy in the Clinic

The LightBench® Detect is the optimal choice for laboratories looking to translate their oncology liquid biopsy workflows into routine clinical practice. You can find out more about how Ranger® Technology can help address the challenges of tumor specific variant profiling in cancer patients by watching this on demand webinar, featuring Kimberly Holden, Research Associate in Oncology Diagnostics Assay Development at Labcorp.

 

Do you like the sound of being able to use EDTA tubes in your NIPT workflow whilst maximising fetal fraction? Read our latest Your Expert article 'Achieving cost savings in NIPT by enabling greater flexibility in blood collection tube choice'or get in touch at This email address is being protected from spambots. You need JavaScript enabled to view it.

If you’re a current IONA® Nx customer interested in becoming an early adopter and working with us on the QS20 validation study, please contact your local account manager, or by using the email This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Reference:  2022. Improving fetal fraction in NIPT by size selection of samples collected in EDTA gel tubes [Poster]. ISPD (26th International Conference on Prenatal Diagnosis and Therapy), 20-22 June 2022, Stand 205.

 

  • Ranger® Revolution - LightBench® Detect is here! - 20 June 2022 +

    Ranger® Revolution - LightBench® Detect is Here!

    The wait is over! Yourgene Health are proud to today reveal the Ranger® Revolution in the form of the LightBench® Detect; the latest addition to our Ranger® Technology portfolio. We’ve worked closely with our clinical laboratory partners to develop a size selection instrument that is optimised for improving the performance of liquid biopsy workflows, most notably non-invasive prenatal testing (NIPT). The LightBench® Detect addresses a pressing need for NIPT

    Read More
  • Collaboration to Perform: Yourgene Microdeletions Plugin Accelerator - 24 May 2022 +

    Yourgene Health is today unveiling the Yourgene Microdeletions Plugin Accelerator phase, following a successful pilot project with LifeStrands Genomics. This Accelerator represents a new era in Yourgene’s approach to delivery of NIPT testing solutions, with a focus on ‘Collaboration to Perform’. Working as a partnership, rather than the traditional laboratory/manufacturer relationship, represents a shared commitment to ensuring high-quality and performance-driven testing, ultimately delivering better outcomes for patients.

    The Plugin has been designed for use with

    Read More
  • Exclusion criteria for NIPT explained - 15 February 2022 +

    The IONA ® test is a non-invasive prenatal test (NIPT) for pregnant women which estimates the risk of a fetus having Down’s syndrome (Trisomy 21), Edwards’ syndrome (Trisomy 18) and Patau’s syndrome (Trisomy 13). The test is performed by analysing cell-free placental-fetal DNA from a maternal blood sample. The test is suitable for women who are at least 10 weeks pregnant, prior to ten weeks there is a risk that there would be insufficient placental-fetal cell

    Read More
  • International Women and Girls in Science Day 2022 +

    Here at Yourgene Health, we are very proud that a large proportion of our genomic technologies and services business, including senior leadership and laboratory managers, are powerful women. We believe it is important to showcase the impressive range of talent we are lucky to have, including our women and girls in science.

    In light of the International Day of Women and Girls in Science, we would like to place a spotlight on a few members

    Read More
  • New Year, New Regulations - 19 January 2022 +

    The ‘New Year's resolution’ is a tradition almost all of us are familiar with, in which a person resolves to accomplish a personal goal, continue good habits or change undesirable ones all with the intention of self-improvement. A study of over 800 million activity data points on the exercise platform Strava found that today, January 19th, is the most common day for a New Year’s resolution to be abandoned ( 1 ). If you are reading this

    Read More
  • Behind the scenes: Adapting diagnostic services during a pandemic - 11 November 2021 +

    The diagnostic testing business has always been dynamic and opportunistic , but nothing could have stretched the definition of these 2 words like a pandemic.

    Since the launch of Yourgene Genomic Services 6 months into this global pandemic – born from a legacy, well established NIPT service laboratory, a modest acquisition, and an unprecedented national genomic testing demand, we have vastly expanded our testing capacity by converting every spare inch of underutilised office space created by remote

    Read More
  • Overprescribing within the NHS - 02 November 2021 +

    “Good for you, good for us but is it good for everybody?”
    Overprescribing within the NHS – October 2021


    The NHS is currently the 5th largest global employer; with over 1.3m employees and receiving around 10% of the UK Government’s annual spending. It is estimated that the NHS deals with 336 million ‘patient visits’ per year, - many of whom will receive some form of at least one ‘prescription’ per visit and at a current charge in

    Read More
  • The role genomics plays in relationships - 18 August 2021 +

    According to National Today, the website dedicated to highlighting every day celebrations and holidays, August 18 th is ‘National Couple’s Day’ – a day to celebrate the important relationships in life. Whilst not an official holiday or observance in any country, the clinical team at Yourgene Health wanted to use this opportunity to reflect upon the pivotal role that genomics plays in relationships across the world.

    Earlier this year a study, published in Nature Human Behaviour,

    Read More
  • NIPT for Sex Chromosome Aneuploidies and Autosomal Aneuploidies. A Q&A with Dr Greg Fitzgibbon - 26 May 2021 +

    Yourgene Health has recently launched IONA ® Care , an advanced prenatal screening test that performs whole-genome analysis to measure the likelihood that a pregnant woman is carrying a fetus with one the most common trisomies (trisomy 21, 18 and 13), any other Autosomal Aneuploidy (AA) or a Sex Chromosome Aneuploidy (SCA). IONA ® Care is available from the Yourgene Genomic Services laboratory in Manchester, UK. The test is available as a menu, enabling pregnant women, their families

    Read More
  • COVID-19 testing and the need for regulation - 6 May 2021 +

    The COVID-19 pandemic presented huge challenges worldwide. In response to the unprecedented need for COVID-19 PCR testing, the UK government set up a new network of Lighthouse laboratories across the country to provide the required capacity for testing thousands of samples each day. These laboratories proved a vital part of the test and trace strategy but were also under immense pressure to meet their targets and, following an investigation by Panorama , it was found that

    Read More
  • Yourgene on World Creativity and Innovation Day 2021 - 21 April 2021 +

    Innovation and creativity are two pillars at the heart of technological and scientific advances. The instrumental role they play has been recognised by the United Nations (UNN), who have designated a special day to raise awareness of the importance of innovation in culture and economic growth worldwide: 21st April. World Creativity and Innovation Day (UNN) is a day to encourage people to “think outside the box”, find new perspectives which push personal growth, identify different

    Read More
  • The IONA® test recommended for twin pregnancies screening for Down’s syndrome - 7 April 2021 +

    In recent years, fertility treatments and the fact women are having babies later has made multiple births more common. In 2016, around 12,000 sets of twins and about 190 sets of triplets or more were born in the UK. That means about 1 in every 65 births in the UK today are twins, triplets or more. 1 Extensive studies have been carried out for cell-free DNA (cfDNA) testing in singleton pregnancies with sample numbers into

    Read More
  • Blood clots, inherited thrombophilia and COVID-19 - 25 March 2021 +

    Recent reports in the media from a collection of European countries suggest that there may be cause for concern with regards to the Oxford AstraZeneca COVID-19 vaccine and abnormal blood clotting. According to Norway’s medicines agency (NoMA), four new cases of “serious blood clotting in adults” have been identified following a recent review (1). Austria have suspended the use of one particular batch of the vaccine after two events, including an individual diagnosed with multiple

    Read More
  • COVID-19 strains - what are they and why do they matter? A Q&A with Dr Michael Risley - 28 January 2021 +

    The COVID-19 pandemic, also known as the coronavirus pandemic, is an ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the beginning of the global COVID-19 outbreak, the diagnostic and research community has undertaken an unprecedented effort to understand how best to manage, eradicate and prevent the disease. In recent months we have seen the rollout of ambitious vaccination schedules worldwide, as well as the strengthening of

    Read More
  • So much to be proud of! - 23 December 2020 +

    As many have already said and written, this year has been like none other. This has been especially true for conferences and exhibitions. Every year, the commercial team at Yourgene look forward to exhibiting at various conferences globally. It’s a chance to meet our partners and customers, as well as form new relationships. With the COVID-19 pandemic none of this was possible, so when we heard that the Taiwan Healthcare Expo was still going ahead,

    Read More
  • 1
  • 2